China Diagnostic Reagent Industry Report,
2011-2012
Oct. 2011
This report
 Analyzes the operating environment of China
Related Products
China Health Management Survey Report, 2011
diagnostic reagent industry
China Oral Hypoglyceimic Agents (OHAs) Industry
Report, 2010
 Focuses on the development of diagnostic reagent
industry
 Highlights the operation of major diagnostic reagent
China Interventional Cardiovascular Device Industry
Report, 2010
China Insulin Industry Report, 2010
manufacturers in China.
China Animal Vaccine Industry Report, 2010-2011
China Blood Products Industry Report, 2010-2011
Please visit our website to order this report and find more
information about other titles at www.researchinchina.com
Abstract
Market Size and Growth Rate of In Vitro Diagnostic Industry in
China, 2007-2014E
Diagnostic reagent can be divided into in vitro diagnostic (IVD) reagent
and in vivo diagnostic reagent, wherein the former always holds a larger
market share in China, accounting for 92.6% in the overall market for
diagnostic reagents in 2010. Despite a late start, China’s IVD reagent
industry has achieved fast development, benefiting from the improved
medical care spending, support of national policies, etc.
The market size of China’s IVD industry reached RMB12.1 billion in
2010, with the compound annual growth rate of up to 13.8% from 2007
to 2010, higher than the global growth of 12.6% over the corresponding
period. Moreover, considering the large population base, improved
economy, etc., China’s IVD reagent industry possesses huge potential
for future growth, which is expected to hit RMB23.2 billion in 2014.
IVD products mainly consist of diagnostic reagents and instruments. In
2010, the market size of IVD reagents climbed 13.3% YoY to RMB9.7
billion in China, occupying 80.2% of the IVD industry. Large-scale
diagnostic reagent manufacturers are often good-sized medical test
equipment producers as well, but many Chinese enterprises only deal
with diagnostic reagents. In China, the high-end diagnostic instrument
market is taken over by foreign brands, such as Hitachi, Toshiba,
Olympus, Sysmex, etc. However, after years of rapid improvement in
the field of diagnostic instrument, Kehua Bio-engineering (KHB) has
become a leading domestic enterprise of diagnostic reagent and
instrument.
Source: ResearchInChina
As far as market segment is concerned, China’s IVD reagents are
still focused on lower-end clinical immunology and clinical chemistry
diagnostic reagents for now, with separate market sizes up to
RMB3.4 billion and RMB3.1 billion in 2010, taking 35% and 32% of
China’s IVD reagent market respectively. In recent years, along with
the launch of nucleic acid blood screening pilot, nucleic acid
diagnostics market has been further expanded, as of the end of
2010, there had already been six pharmaceutical factories to declare
nucleic acid blood screening reagents to the State Food and Drug
Administration (SFDA), namely, KHB, Da An Gene, Haoyuan
Biotech, PG Biotech (later acquired by QIAGEN), Roche and
Novartis Diagnostics, which will benefit from the nucleic acid blood
screening pilot and subsequent marketing.
Table of contents
1. Industry Profile
1.1 Definition and Classification
1.2 Industrial Chain
1.2.1 Upstream Market
1.2.2 Downstream Market
3.6 Development Tendency of Diagnostic
Reagent Sector in China
4.5 Beijing Kinghawk Pharmaceutical Co., Ltd.
4.5.1 Profile
4.5.2 Operation
4.5.3 Prospects and Dynamics
4. Major Domestic Producers
4.6 Zhuhai Livzon Diagnostics Inc.
4.1 Shanghai Kehua Bio-Engineering
4.6.1 Profile
Co., Ltd. (KHB)
4.6.2 Operation
4.1.1
Profile
4.7 ACON Biotech (Hangzhou) Co., Ltd.
2. Operating Environment in China
4.7.1 Profile
4.1.2
Operation
2.1 Global Market
4.7.2 Operation
2.1.1 Development of Biopharmaceutical Industry 4.1.3 Diagnostic Reagent Business
4.8 Beijing Wantai Biological Pharmacy
Worldwide
4.1.4 Prospects and Dynamics
Enterprise Co., Ltd.
2.1.2 Development of Diagnostic Reagent Industry 4.2 Da An Gene Co., Ltd. of Sun Yat-Sen
4.9 Shanghai Rongsheng Biotech Co., Ltd.
Worldwide
University
4.10 Shenzhen PG Biotech Co., Ltd.
2.2 Chinese Market
4.2.1 Profile
4.10.1 Profile
4.10.2 Major Products
2.2.1 Development of Biopharmaceutical Industry 4.2.2 Operation
in China
4.11 Shanghai Upper Bio-Tech Pharma Co., Ltd.
4.2.3 Diagnostic Reagent Business
4.12 Beijing Leadman Biochemistry Co., Ltd.
2.2.2 Relevant Policies of China
4.2.4 Prospects and Dynamics
4.12.1 Profile
4.3 Fosun Pharmaceutical (Group)Co., Ltd. 4.12.2 Operation
3. Development in China
4.3.1 Profile
4.12.3 Prospects and Dynamics
3.1 Status Quo
4.13 Blue Cross Bio-Medical (Beijing) Co., Ltd.
4.3.2 Operation
3.2 Market Size
4.14 Inverness Medical (Shanghai)Co., Ltd.
4.3.3 Prospects and Dynamics
4.15 Baso Diagnostics Inc.
3.3 Competition Pattern
4.3.4 Shanghai Fosun Long March Medical
4.16 Beijing North Institute of Biological
3.4 Import & Export
Science Co., Ltd.
Technology
3.4.1 Import
4.3.5 Shanghai Fosun Med-Tech
4.17 Xiamen Boson Biotech Co., Ltd.
3.4.2 Export
Development Co., Ltd.
3.5 Market Segments
4.4 Biosino Bio-Technology & Science Inc.
3.5.1 Biochemistry Diagnostic Reagent
4.4.1 Profile
3.5.2 Immune Diagnostic Reagent
4.4.2 Operation
3.5.3 Nucleic Acid Diagnostic Reagent
4.4.3 Prospects and Dynamics
Selected Charts
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Global Biopharmaceutical Market Scale, 2007-2012
Global Biopharmaceutical Revenue by Region, 2009
Market Size of IVD Industry Worldwide, 2008-2012
China’s Biopharmaceutical Sales and YoY Growth, 2005-Jan-May 2011
Relevant Polices of Diagnostic Reagent Industry in China
Product Structure of Diagnostic Reagent Industry in China, 2010
Structure of In Vitro Diagnostic Reagents in China, 2010
Market Size and Growth Rate of In Vitro Diagnostic Industry in China, 2007-2014
Market Size and Growth Rate of In Vitro Diagnostic Reagents in China, 2007-2014
Major Manufacturers of IVD Products in China
China’s Import Value, Import Volume and Average Price of Contrast Agent for X-Ray Inspection and Diagnostic Reagent for
Patients, 2007-Jan.-Aug. 2011
China’s Accumulated Import Volume & Value and Proportion of Contrast Agent for X-Ray Inspection and Diagnostic Reagent
for Patients by Country of Origin, Jan.-Aug. 2011
Distribution of China’s Imported Contrast Agent for X-Ray Inspection and Diagnostic Reagent for Patients by Destination,
2008- Jan- Aug.2011
China’s Export Value, Export Volume and Average Price of Contrast Agent for X-Ray Inspection and Diagnostic Reagent for
Patients by Destination, 2007-Jan.-Aug. 2011
China’s Accumulated Export Volume & Value and Proportion of Contrast Agent for X-Ray Inspection and Diagnostic Reagent
for Patients by Destination, Jan.-Aug. 2011
Export Origins Distribution of China’s Contrast Agent for X-Ray Inspection and Diagnostic Reagent for Patients, Jan.-Aug.
2011
China’s Biochemical Reagent Market Scale, 2007-2014
China’s Immune Reagent Market Scale, 2007-2014
Operating Revenue and Net Income of KHB, 2006- H1 2011
Selected Charts
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Gross Margin of KHB by Product, 2008-H1 2011
Proportion of Operating Revenue of KHB by Region, 2008-H1 2011
Diagnostic Reagent Products of KHB
Operating Revenue and Gross Margin of KHB, 2011-2013E
Operating Revenue and Net Income of Da An Gene, 2006- H1 2011
Operating Revenue of Da An Gene by Product, 2007- H1 2011
Gross Margin of Da An Gene by Product, 2008-H1 2011
Proportion of Operating Revenue of Da An Gene by Region, 2008-H1 2011
R&D Input and Its Ratio to Operating Revenue of Da An Gene, 2008-2010
Operating Revenue and Gross Margin of Da An Gene, 2011-2013E
Operating Revenue and Net Income of Fosun Pharmaceutical (Group), 2006- H1 2011
Operating Revenue and Gross Margin of Fosun Pharmaceutical (Group), 2011-2013E
Operation of Shanghai Fosun Long March Medical Science, 2008-2009
Operation of Shanghai Fosun Med-Tech Development, 2008-2009
Operating Revenue and Net Income of Biosino Bio-Technology & Science, 2006- H1 2011
Operating Revenue of Biosino Bio-Technology & Science by Product, 2008- H1 2011
Licenses and Patents for In-vitro Diagnostic Reagents of Biosino Bio-Technology& Science, 2010
Operating Revenue and Net Income of Beijing Kinghawk Pharmaceutical, 2008- H1 2011
Operating Revenue of Beijing Kinghawk Pharmaceutical (by Product), 2010- H1 2011
Operating Revenue of Beijing Kinghawk Pharmaceutical (by Region), 2010- H1 2011
Operating Revenue of Zhuhai Livzon Diagnostics, 2007- H1 2011
Certificate Acquired by Zhuhai Livzon Diagnostics, Jun.2010-Sep.2011
Operation of ACON Biotech, 2008-2009
Certificate Acquired by ACON Biotech for the Registration of Medical Devices, Mar. 2010 & May 2011
Operation of Beijing Wantai Biological Pharmacy, 2008-2009
Selected Charts
•
•
•
•
•
•
•
•
•
•
•
Operation of Shanghai Rongsheng Biotech, 2008-2009
Operation of PG Biotech, 2008
Detection Reagent of PG Biotech
Operation of Shanghai Upper Bio-Tech Pharma, 2008-2009
Diagnostic Reagents and Diagnostic Instruments of Shanghai Upper Bio-Tech Pharma
Operation of Beijing Leadman Biochemistry, 2008-2009
Operation of Blue Cross Bio-Medical (Beijing), 2008-2009
Operation of Inverness Medical (Shanghai), 2008-2009
Operation of Baso Diagnostics, 2008-2009
Operation of Beijing North Institute of Biological Technology, 2008-2009
Operation of Boson Biotech, 2009
How to Buy
You can place your order in the following alternative ways:
Choose type of format
1.Order online at www.researchinchina.com
Hard copy
2.Fax order sheet to us at fax number:+86 10 82601570
PDF (Single user license) ………......1500 USD
3. Email your order to: report@researchinchina.com
PDF (Enterprisewide license)….. ......2300 USD
…………………………1600 USD
4. Phone us at +86 10 82600828/ 82600893
Party A:
Name:
Address:
Contact Person:
E-mail:
※ Reports will be dispatched immediately
once full payment has been received.
Tel
Fax
Payment may be made by wire transfer or
Party B:
Name:
Address:
Beijing Waterwood Technologies Co., Ltd (ResearchInChina)
Room 1008, A2, Tower A, Changyuan Tiandi Building, No. 18, Suzhou
Street, Haidian District, Beijing, China 100080
Liao Yan
Phone: 86-10-82600828
credit card via Paypal.
Contact
Person:
E-mail:
report@researchinchina.com
Fax:
86-10-82601570
Bank details: Beneficial Name: Beijing Waterwood Technologies Co., Ltd
Bank Name: Bank of Communications, Beijing Branch
Bank Address: NO.1 jinxiyuan shijicheng,Landianchang,Haidian
District,Beijing
Bank Account No #: 110060668012015061217
Routing No # : 332906
Bank SWIFT Code: COMMCNSHBJG
Title
Format
Cost
Total
Room 1008, A2, Tower A, Changyuan Tiandi Building, No. 18, Suzhou Street, Haidian District, Beijing, China 100080
Phone: +86 10 82600828 ● Fax: +86 10 82601570 ● www.researchinchina.com ● report@researchinchina.com